We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The U.S. Court of Appeals for the District of Columbia has rejected petitions from a cohort of drug and devicemakers that seek to overrule a decision last year allowing to proceed a lawsuit accusing the companies of indirectly funding terrorist acts in Iraq. Read More
The European Medicines Agency (EMA) has launched a new pilot program that gives some study leeway to drugmakers working on pediatric investigation plans (PIP) for innovative children’s medicines. Read More
A federal court has rejected a lawsuit from the Pharmaceutical Research and Manufacturers of America (PhRMA) filed against HHS that would seek to block states from importing prescription drugs from Canada. Read More
In his State of the Union address on Tuesday night, President Biden continued pressing for a $35-per-month limit on insulin for diabetics of all ages. Read More
Drugmakers have a long way to go when it comes to fulfilling their required postmarket reporting, according to the FDA’s most recent numbers. Read More
The European Medicines Agency (EMA) is requesting public comment on its new multi-stakeholder platform, Accelerating Clinical Trials (ACT) EU, for improving clinical trials within the trade bloc. Read More
Sage Therapeutics and Biogen announced Monday that the FDA has given priority review to the companies’ new drug application (NDA) for zuranolone for the treatment of major depressive disorder (MDD) and postpartum depression (PPD). Read More
In a case with wide-ranging implications for how broad patent protections can be, Sanofi and Regeneron are calling on the Supreme Court to deny Amgen’s attempt to overturn an appeals court’s rejection of Amgen’s patent for its blockbuster cholesterol treatment Repatha (evolocumab). Read More